|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: F13A1 |
Gene summary for F13A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | F13A1 | Gene ID | 2162 |
| Gene name | coagulation factor XIII A chain | |
| Gene Alias | F13A | |
| Cytomap | 6p25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P00488 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2162 | F13A1 | C09 | Human | Oral cavity | OSCC | 4.57e-03 | 5.24e-01 | 0.1431 |
| 2162 | F13A1 | SYSMH5 | Human | Oral cavity | OSCC | 4.43e-03 | 1.14e+00 | 0.0647 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
| GO:005087819 | Oral cavity | OSCC | regulation of body fluid levels | 179/7305 | 379/18723 | 6.19e-04 | 3.50e-03 | 179 |
| GO:00075969 | Oral cavity | OSCC | blood coagulation | 102/7305 | 217/18723 | 9.69e-03 | 3.43e-02 | 102 |
| GO:00075999 | Oral cavity | OSCC | hemostasis | 103/7305 | 222/18723 | 1.45e-02 | 4.73e-02 | 103 |
| GO:00508179 | Oral cavity | OSCC | coagulation | 103/7305 | 222/18723 | 1.45e-02 | 4.73e-02 | 103 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| F13A1 | SNV | Missense_Mutation | c.1141N>T | p.Met381Leu | p.M381L | P00488 | protein_coding | deleterious(0.03) | possibly_damaging(0.741) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| F13A1 | SNV | Missense_Mutation | c.1262N>A | p.Gly421Asp | p.G421D | P00488 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| F13A1 | SNV | Missense_Mutation | c.2057N>A | p.Pro686His | p.P686H | P00488 | protein_coding | deleterious(0.03) | probably_damaging(0.969) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| F13A1 | SNV | Missense_Mutation | c.1319N>A | p.Leu440His | p.L440H | P00488 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| F13A1 | SNV | Missense_Mutation | rs776782223 | c.475C>T | p.Arg159Cys | p.R159C | P00488 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-Z7-A8R5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| F13A1 | insertion | Nonsense_Mutation | novel | c.1976_1977insTTCAGACTCAGGCTGGTGAATTCCAGAACCCAAGTTTG | p.Glu659AspfsTer7 | p.E659Dfs*7 | P00488 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| F13A1 | insertion | Frame_Shift_Ins | novel | c.1915_1916insACTCAGCCTTGCAAATAGCCAGTGCTAGTTCTGACCC | p.Gly639AspfsTer20 | p.G639Dfs*20 | P00488 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| F13A1 | insertion | In_Frame_Ins | novel | c.149_150insGCATGAGACACCATGCCCAGCCTTTAACCTCCTCTTGAAGATTAA | p.Ser50delinsArgHisGluThrProCysProAlaPheAsnLeuLeuLeuLysIleAsn | p.S50delinsRHETPCPAFNLLLKIN | P00488 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| F13A1 | SNV | Missense_Mutation | rs796662757 | c.931C>T | p.Arg311Trp | p.R311W | P00488 | protein_coding | deleterious(0.02) | possibly_damaging(0.764) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| F13A1 | SNV | Missense_Mutation | c.707T>C | p.Leu236Pro | p.L236P | P00488 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2162 | F13A1 | DRUGGABLE GENOME, ENZYME | photodynamic therapy | |||
| 2162 | F13A1 | DRUGGABLE GENOME, ENZYME | PMID26560530-Compound-13 | |||
| 2162 | F13A1 | DRUGGABLE GENOME, ENZYME | aspirin | ASPIRIN | 12515735 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |